	US 12,274,808 B2
	Collagen-based therapeutic delivery systems
Sherry Voytik-Harbin, Zionsville, IN (US); and Rucha Joshi, Davis, CA (US)
Assigned to PURDUE RESEARCH FOUNDATION, West Lafayette, IN (US)
Filed by PURDUE RESEARCH FOUNDATION, West Lafayette, IN (US)
Filed on Jun. 30, 2022, as Appl. No. 17/854,139.
Application 16/436,636 is a division of application No. 15/505,046, granted, now 10,314,940, issued on Jun. 11, 2019, previously published as PCT/US2015/047176, filed on Aug. 27, 2015.
Application 17/854,139 is a continuation of application No. 16/436,636, filed on Jun. 10, 2019, abandoned.
Claims priority of provisional application 62/042,664, filed on Aug. 27, 2014.
Prior Publication US 2023/0068180 A1, Mar. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61L 27/24 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 38/18 (2006.01); A61K 47/42 (2017.01); A61L 27/54 (2006.01)

CPC A61L 27/24 (2013.01) [A61K 9/0024 (2013.01); A61K 9/19 (2013.01); A61K 38/18 (2013.01); A61K 47/42 (2013.01); A61L 27/54 (2013.01); A61L 2300/414 (2013.01); A61L 2300/604 (2013.01); A61L 2400/06 (2013.01)]

18 Claims

1. A collagen-based therapeutic delivery device comprising:

an insoluble synthetic collagen-fibril matrix comprising a polymerization product of a mixture of soluble oligomeric collagen with soluble telocollagen molecules; and

a therapeutic drug dispersed within the insoluble synthetic collagen-fibril matrix, said therapeutic drug being selected from the group consisting of an antimicrobial, a protease, an antibiotic, an oncostatic agent, a chemotherapeutic, an immunomodulator, a tumor necrosis factor, an interleukin and an interferon;

wherein the collagen-fibril matrix lacks cell and exhibits a stiffness of at least 5 Pa in the absence of an exogenous cross-linking agent.